$125.1B of 2025 oncology blockbuster sales lose US exclusivity by 2037, led by Keytruda, Darzalex, Opdivo. These 24 public biotechs have 35 oncology treatments in Phase 3 or filed with the FDA, 4 of them already filed.
2025 sales each company reports from tracked oncology treatments losing US exclusivity by 2037. Big pharma has spent $102.7B on 20 oncology acquisitions since 2023. See the deals →
Biliary cancer survival results strengthen expansion potential; lung cancer FDA decision remains central
Gio drives growth; Pax adoption weakens ahead of brain-metastases decision
Zipalertinib approval routes advance; velinotamig broadens Cullinan's autoimmune pipeline
Karyopharm's lenders extended their forbearance to November 1 while FDA decides whether to accept its sNDA for selinexor plus ruxolitinib in myelofibrosis; the company has warned it may not continue as a going concern
Ascentage's China sales are growing; lisaftoclax awaits reimbursement and global Phase 3 data
Casdatifan leads Arcus's case; completed equity raise strengthens funding while diluting ownership
Candel plans to file its prostate cancer BLA for aglatimagene in Q4 2026
Immunocore's TEBE-AM Phase 3 in cutaneous melanoma could read out by year-end
Keros dosed the first patient in rinvatercept's Phase 2 in Duchenne muscular dystrophy, with initial data due in 1H 2027; Takeda's elritercept Phase 3s are paying milestones
Actinium rebuilt its equity, but Actimab-A has no dated results
ARR-217 responses strengthen ADC opportunity; firmonertinib's post-FURVENT path remains uncertain
FDA wants a survival trial before Compass can file tovecimig in biliary cancer
Soquelitinib's Phase 2 SIERRA1 trial must confirm small Phase 1 atopic dermatitis results
Greenwich runs a Phase III breast cancer trial with $8.9 million of cash
SUPRAME remains central; IMA402 responses support a selective, early-stage PRAME opportunity
Imunon is enrolling its Phase 3 OVATION 3 trial of IMNN-001 in newly diagnosed advanced ovarian cancer faster than planned, after Phase 2 showed median survival 14.7 months longer; cash of $6.9 million and a going-concern warning make funding the main risk
Ateganosine's THIO-104 Phase 3 against chemotherapy is enrolling, and MAIA says it must raise more money
MIRACLE Part A dosing complete; results and funding remain pivotal
Enozertinib responses support Redwood-1 plans alongside ongoing Himalayas-1
TUDRIQEV gains early adoption; RP2's REVEAL transition next, confirmatory funding uncertain
Longer runway supports ersodetug plans; upLIFT and congenital HI filing remain pivotal
GPS enters REGAL final analysis; SLS009 first-line AML data remain expected Q4 2026
TransCode explores strategic deals as funding pressure persists
Zentalis expects integrated DENALI Part 2 data for azenosertib in Cyclin E1-positive ovarian cancer in the first half of 2027, after FDA said the population could support accelerated approval; Part 1b data showed median survival of 15.9 months in Cyclin E1-positive patients
Filed treatments are listed first. This shows where late-stage treatments are being developed, not which companies will be acquired.
Pipeline data and summaries from Readouts as of 13 November 2026; companies already acquired are left out.
Immunology · Cardiometabolic · Infectious disease · Neuroscience · Other areas